Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Jan 7, 2015
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Exercise/Conversion
Common Stock, no par value
2015-01-05+45,000→ 318,714 total - Tax Payment
Common Stock, no par value
2015-01-05−23,600→ 295,114 total - Exercise/Conversion
Restricted Share Units
2015-01-05−45,000→ 22,500 total→ Common Stock (22,500 underlying)
Footnotes (3)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $42.70 starting on December 1, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 1, 2014, 50% on December 1, 2014 and 25% on March 1, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels.
- [F2]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.
- [F3]Represents the maximum number of Common Shares that may be issued under the RSU award. See note 1.